News Breaks |
|
|
| November 26, 2012 |
| 10:23 EDT |  | BSX, MDT, STJ | Boston Scientific rises after Citi sees Durata coming off market
Boston Scientific (BSX) is climbing after Citigroup analyst Matthew Dodds upgraded the stock to Buy from Neutral in a note to investors earlier today. Durata cables made by St. Jude (STJ), a Boston Scientific competitor, will likely be taken off the market within six months, Dodds believes. Earlier this year a study found that Durata cables can fray when they rub against another object. Boston Scientific will benefit significantly from the withdrawal of St. Jude's cables, which are used to connect defibrillators to the heart, Dodds wrote. If Durata cables are removed from the market, Boston Scientific would obtain 41% of the $338M in revenue that St. Jude would lose, the analyst predicted. Medtronic (MDT) will garner 29% of St. Jude's lost sales, adds Dodds. The analyst increased his price target on Boston Scientific to $7.30 from $5.30. In mid-morning trading, Boston Scientific climbed 19c, or 3.40%, to $5.78, while St. Jude fell 35c, or 1.09%, to $31.68. |
|
|
News For BSX;STJ;MDT From The Last 14 Days Check below for free stories on BSX;STJ;MDT the last two weeks. |
|
|
| May 23, 2013 |
| 05:44 EDT | | STJ | St. Jude Medical study of EnligHTN shows sustained blood pressure reduction
St. Jude Medical announced that the company's EnligHTN Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after one year. Patients enrolled in the EnligHTN I trial had an average blood pressure of 176 / 96 mmHg and patients were drug-resistant, meaning their blood pressure could not be controlled through medication. At one year, patients treated with the EnligHTN Renal Denervation System experienced an average systolic blood pressure reduction of 27 mmHg points when measured in an office setting. |
|
| 05:40 EDT | | MDT | Medtronic CoreValue system gains CE mark for transcatheter VIV procedures
 Subscribe for More Information |
|
| 05:38 EDT | | MDT | Medtronic's In.Pact Falcon yields positive outcomes in small coronary arteries
Subscribe for More Information |
|
| May 22, 2013 |
| 12:22 EDT | | BSX | Boston Scientific says new data shows blood pressure reduction with Vessix
Boston Scientific reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented at the annual EuroPCR Scientific Program in Paris. Interim data highlights include: All patients underwent successful bilateral renal denervation treatment; At the primary endpoint of six months, patients experienced a significant 27.6 mmHg reduction in systolic blood pressure; No device-related adverse events or procedural renal artery complications were reported; Long term efficacy was demonstrated, with a sustained 28.4 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available; Demonstrated success in treating various anatomies, including accessory renal arteries; Demonstrated short renal denervation procedural time. |
|
| 10:44 EDT | | BSX | Boston Scientific says Lotus system met primary performance endpoint in trial
Subscribe for More Information |
|
| 09:35 EDT | | BSX | Boston Scientific says trials show 'exceptional' safety, efficacy data on stents
Boston Scientific reported positive results from two trials evaluating new, innovative drug-eluting stent technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the safety and effectiveness of the SYNERGY Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System to the PROMUS Element Stent System were presented at the annual EuroPCR Scientific Program in Paris. The primary investigator for one trial said, "The Promus PREMIER Stent demonstrated excellent safety and effectiveness with zero percent target lesion revascularization and stent thrombosis. In addition, the rate of technical success, the primary endpoint of the trial, was very high at 99.2%." |
|
| 07:48 EDT |  | MDT | FDA Orthopaedic and Rehabilitation Devices Panel to hold a meeting
Subscribe for More Information |
|
| May 21, 2013 |
| 13:02 EDT | | MDT | Medtronic announces CE Mark for CapSureFix Novus
Medtronic announced CE Mark and launch of its CapSureFix Novus 5076 Lead, which is now approved in the EU for use in an MRI environment when paired with a Medtronic MR-Conditional pacemaker. The lead has not been approved for that use in the U.S. |
|
| 11:49 EDT | | BSX | Boston Scientific data show Bronchial Thermoplasty benefits for up to five years
Subscribe for More Information |
|
| 11:38 EDT |  | MDT | High option volume stocks: KOS MWE HGG SOL MDT
|
| |
| 09:25 EDT | | MDT | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 07:19 EDT |  | MDT | Medtronic sees FY14 EPS $3.80-$3.85, consensus $3.84
Sees FY14 revenue growth up 3%-4% on a constant currency basis. |
|
| 07:17 EDT | | MDT | Medtronic reports Q4 EPS $1.10, consensus $1.03
Subscribe for More Information |
|
| 05:54 EDT | | MDT | Medtronic announces primary results from Global Symplicity Registry
Subscribe for More Information |
|
| 05:51 EDT | | MDT | Medtronic CoreValue ADVANCE study shows low mortality rates
Subscribe for More Information |
|
| 05:48 EDT | | BSX | OrbusNeich seizes Boston Scientific stents as part of patent infringement case
Subscribe for More Information |
|
| May 20, 2013 |
| 15:22 EDT | | MDT | Notable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Home Depot (HD), consensus 77c; Medtronic (MDT), consensus $1.03; The TJX Companies (TJX), consensus 62c; AutoZone (AZO), consensus $7.23; Best Buy (BBY), consensus 25c; Dick's Sporting Goods (DKS), consensus 48c; Tidewater (TDW), consensus 61c; Saks (SKS), consensus 19c; Rexnord (RXN), consensus 31c; Monro Muffler Brake (MNRO), consensus 25c. |
|
| 11:12 EDT | | STJ | St. Jude Medical to evaluate defibrilator lead related to reported death
Subscribe for More Information |
|
| 09:41 EDT | | BSX, MDT | Supreme Court agrees to hear Medtronic-Boston Scientific patent case
Reported by SCOTUSblog live blog of court orders and opinions. |
|
| 07:11 EDT | | MDT | Medtronic receives CE mark for 'export advance' aspiration catheter
Subscribe for More Information |
| |
|
|
|
|
